Plasmodium vivax promiscuous T-helper epitopes defined and evaluated as linear peptide chimera immunogens

Infection and Immunity

Volumn 70, Issue 7, 2002, Pages 3479-3492

  Caro Aguilar, Ivette ^a   Rodríguez, Alexandra ^a   Calvo Calle, J Mauricio ^a   Guzmán, Fanny ^a   De la Vega, Patricia ^a   Patarroyo, Manuel Elkin ^a   Galinski, Mary R ^a   Moreno, Alberto ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; EPITOPE; GAMMA INTERFERON; INTERLEUKIN 5; MALARIA VACCINE; SYNTHETIC PEPTIDE;

ANIMAL MODEL; ARTICLE; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALARIA; MOUSE; NONHUMAN; PLASMODIUM VIVAX; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, PROTOZOAN; EPITOPE MAPPING; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; FEMALE; HLA-DR ANTIGENS; HUMANS; MEROZOITE SURFACE PROTEIN 1; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PEPTIDES; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PROTOZOAN PROTEINS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 0036084730     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.70.7.3479-3492.2002     Document Type: Article

References (69)

1. Low response of Colombian strains of Plasmodium vivax to classical antimalarial therapy
2. Synthesis and construction of a novel multiple peptide conjugate system: Strategy for a subunit vaccine design
3. The ears of the hippopotamus: Manifestations, determinants, and estimates of the malaria burden
4. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1
5. Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: Identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein
6. Polymorphism in Plasmodium vivax MSA1 gene-the result of intragenic recombinations?
7. A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses
8. The antibody response in mice to carrier-free synthetic polymers of Plasmodium falciparum circumsporozoite repetitive epitope is I-Ab-restricted: Possible implications for malaria vaccines
9. Primary structure of the merozoite surface antigen 1 of Plasmodium vivax reveals sequences conserved between different Plasmodium species
10. Antigenic properties of the merozoite surface protein 1 gene of Plasmodium vivax
11. Universal epitopes for human CD4+ cells on tetanus and diphtheria toxins
12. HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles
13. Phylogeny of the malarial genus Plasmodium, derived from rRNA gene sequences
14. An altered peptide ligand inhibits the activities of matrix metallopro-teinase-9 and phospholipase C, and inhibits T cell interactions with VCAM-1 induced in vivo by a myasthenogenic T cell epitope
15. Allele-specific motifs revealed by sequencing of self peptides eluted from MHC molecules
16. Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against Semliki Forest virus
17. Induction of HIV-1 IIIb neutralizing antibodies in BALB/c mice by a chimaeric peptide consisting of a T-helper cell epitope of Semliki Forest virus and a B-cell epitope of HIV
18. Epitope polarity and adjuvants influence the fine specificity of the humoral response against Semliki Forest virus specific peptide vaccines
19. A simple screening method for detecting bindings between oligopeptides and HLA-DR molecules on filter papers: Possible application for mapping of putative helper T-cell epitopes on MSP1 of Plasmodium falciparum
20. A reticulocyte-binding protein complex of Plasmodium vivax merozoites
21. Immune responses to Plasmodium falciparum-merozoite surface protein 1 (MSP1) antigen. II. Induction of parasite-specific immunoglobulin G in unsensitized human B cells after in vitro T-cell priming with MSP119
22. Structure and expression of the gene for Pv200, a major blood-stage surface antigen of Plasmodium vivax
23. Development of immunity to malaria may not be an entirely active process
24. Immune effector mechanisms in malaria
25. An avidin-biotin-peroxidase assay to detect synthetic peptides bound to polystyrene plates
26. Plasmodium vivax: Polymorphism in the merozoite surface protein 1 gene from wild Colombian isolates
27. Identification of a motif for HLA-DR1 binding peptides using M13 phage display libraries
28. Promiscuous and allele-specific anchors in HLA-DR-binding peptides
29. Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning
30. Peptide binding specificity of HLA-DR4 molecules: Correlation with rheumatoid arthritis association
31. HLA class II peptide binding specificity and autoimmunity
32. New World monkey efficacy trials for malaria vaccine development: Critical path or detour?
33. Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria
34. General method for the rapid solid-phase synthesis of large numbers of peptides: Specificity of antigen-antibody interaction at the level of individual amino acids
35. Primary response of naive CD4(+) T cells to amino acid-substituted analogs of an antigenic peptide can show distinct activation patterns: Th1- and Th2-type cytokine secretion, and helper activity for antibody production without apparent cytokine secretion
36. Preparation and properties of totally synthetic immunogens
37. Crystallographic analysis of endogenous peptides associated with HLA-DR1 suggests a common, polyproline II-like conformation for bound peptides
38. Peptide binding and antigen presentation by class II histocompatibility glycoproteins
39. Immunogenicity of well-characterized synthetic Plasmodium falciparum multiple antigen peptide conjugates
40. Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid
41. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen
42. Immunogenicity of Plasmodium falciparum circumsporozoite protein multiple antigen peptide vaccine formulated with different adjuvants
43. Characterization of SPf(66)n: A chimeric molecule used as a malaria vaccine
44. The measurement of relative antibody affinity by ELISA using thiocyanate elution
45. Cytotoxic CD4+ T cells from a sporozoite-immunized volunteer recognize the Plasmodium falciparum CS protein
46. CD4+ T cell clones obtained from Plasmodium falciparum sporozoite-immunized volunteers recognize polymorphic sequences of the circumsporozoite protein
47. Immunogenicity of multiple antigen peptides (MAP) containing T and B cell epitopes of the repeat region of the P. falciparum circumsporozoite protein
48. Conserved repetitive epitope recognized by CD4+ clones from a malaria-immunized volunteer
49. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes
50. A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types
51. Malaria: New developments in treatment and prevention
52. Specificity of protective immunity produced by x-irradiated Plasmodium berghei sporozoites
53. Progress in malaria vaccine development: Characterization of protective antigens
54. Antisporozoite vaccine for malaria: Experimental basis and current status
55. Colinear synthesis of an antigen-specific B-cell epitope with a 'promiscuous' tetanus toxin T-cell epitope: A synthetic peptide immunocontraceptive
56. Characterization of conserved T- and B-cell epitopes in Plasmodium falciparum major merozoite surface protein 1
57. Lack of H-2 restriction of the Plasmodium falciparum (NANP) sequence as multiple antigen peptide
58. Assessing the binding of four Plasmodium falciparum T helper cell epitopes to HLA-DQ and induction of T-cell responses in HLA-DQ transgenic mice
59. Studies in owl monkeys leading to the development of a synthetic vaccine against the asexual blood stages of Plasmodium falciparum
60. Peptide dose, affinity, and time of differentiation can contribute to the Th1/Th2 cytokine balance
61. Quantitative monitoring of solid-phase peptide synthesis by the ninhydrin reaction
62. A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules
63. Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria
64. Synthetic peptides: A modern approach to vaccination
65. Several common HLA-DR types share largely overlapping peptide binding repertoires
66. Are trials in New World monkeys on the critical path for blood-stage malaria vaccine development?
67. Central role of endogenous gamma interferon in protective immunity against blood-stage Plasmodium chabaudi AS infection
68. Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria
69. Role of adjuvants in the modulation of antibody isotype, specificity, and induction of protection by whole blood-stage Plasmodium yoelii vaccines